1899Yamada Yasutami founds the Shintendō pharmacy; launches the stomach remedy Ikatsu
1909Rohto Eye Drops launched
1949Reorganised as Rohto Pharmaceutical Co., Ltd.
Rohto began in February 1899, when Yamada Yasutami opened the Shintendō Yamada Yasutami Pharmacy in Osaka and started making and selling a stomach remedy called Ikatsu. The eye-drop line that would carry the company came a decade later — Rohto Eye Drops in 1909, named for the German Munich University professor Rothmund, whose formulation they adapted — and demand jumped again in 1931 when Rohto devised its own dropper bottle. The firm pushed abroad in the 1930s, setting up subsidiaries in Shanghai (1938) and Mukden (1941), only to lose those overseas assets outright when the Pacific War ended and the business snapped back to Japan.
In September 1949 the family reorganised the private business into a joint-stock company, Rohto Pharmaceutical Co., Ltd., with capital of $27,778 (¥10m). The second-generation head, Terurō Yamada, took the presidency and deliberately kept outside capital at arm’s length, so that most large shareholders remained members of the Yamada family. That choice fused ownership and control at the outset — a base of independence that would let every later decision be taken on the family’s own judgement rather than the market’s.
1961Listed on the second section of the Osaka exchange
1964Designated to the first sections of the Osaka and Tokyo exchanges
1975Acquires the Mentholatum trademark licence
1983Loses the domestic top share in stomach medicine
1988Buys the American Mentholatum Company outright
Through the 1950s and 1960s Rohto built the model it is still known for. Terurō Yamada narrowed the catalogue and mass-produced a few good products cheaply, pouring the advertising budget into a handful of names — Shiron (1954), Pansyron (1963) and the premium V-Rohto eye drops (1964), distributed through a nationwide dealer network, the Rohto-kai, formed in 1964. Where rivals ran many overlapping lines, Rohto did the opposite, squeezing manufacturing and selling costs into high-turnover profit and taking roughly 40% of the domestic market in both stomach remedies and eye drops. It listed on the second section of the Osaka exchange in 1961 and moved to the first sections of Osaka and Tokyo in 1964.
Then the strength inverted. As the stomach-medicine market matured in the late 1970s, rivals attacked it symptom by symptom — heartburn, bloating, over-indulgence — each with its own targeted product and advertising, while Rohto kept flying the all-purpose Pansyron banner. In 1983 it ceded the domestic top share in stomach medicine, and the position never came back: the few-SKU focus that had won an expanding market lacked the agility to answer a fragmenting one.
Rohto had, however, been building a cushion. In August 1975 it acquired from the American Mentholatum Company the right to use the Mentholatum trademark — left in limbo by the collapse of Ōmi Kyōdaisha — and entered the ointment market, taking a known brand rather than building one, on a ten-year licence at a royalty of 7.5% of sales. That third earnings stream is what kept the stomach-medicine setback from denting the whole business. Thirteen years later Rohto went further: in July 1988 it bought the Mentholatum Company itself, converting the ointment business from a contract into outright ownership of manufacturing, sales and the mark — its first full-scale overseas acquisition and the seed of everything that followed abroad.
1991China joint venture — Rohto’s first step into Asia
1996Rohto Indonesia established; sponsors China’s Atlanta diving team
1998Rohto USA established at Orchard Park
1999Kunio Yamada becomes president
Owning the source changed the game. With price-setting and product decisions now in its own hands, Rohto made Mentholatum the axis of an international business rather than a domestic ointment brand — even as Ōmi Kyōdaisha returned home under the Mentāmu name to make it a three-way domestic contest. In 1991 Rohto set up a joint venture in China with the Mentholatum Company, its first real step into Asia, and at the 1996 Atlanta Olympics it sponsored China’s diving team, whose six gold medals carried the brand’s recognition across the market at little advertising cost.
The network filled in quickly: Rohto Indonesia in 1996 and Rohto-Mentholatum Indonesia in 1997 built a Southeast Asian production and sales base, and in 1998 Rohto USA was established at Orchard Park, home of the Mentholatum Company’s headquarters and plant. Anchored on China, the Asia business grew into a third pillar behind Japan and the United States, and the overseas share of sales rose — the brand sovereignty won in the 1988 buyout turning, a decade on, into revenue across a spread of local operations. In 1999 Yasukuni Yamada moved up to chairman and Kunio Yamada became president.
2019Masashi Sugimoto — first president from outside the family
2022Three straight years of margin improvement
From 2001 Rohto invested seriously in skincare, applying the dermatological knowledge built up in drug development to a high-concentration hyaluronic-acid lotion, Hada Labo. Crossing into cosmetics — a field where drug makers had rarely succeeded — it competed on how well ingredients worked and how cheaply, a fit for the fast-growing drugstore channel, and Hada Labo grew from skincare sales of about $226.5M (¥24bn) in fiscal 2000 into a fourth pillar alongside stomach medicine, eye drops and ointments. A 2003 strategic tie-up with Morishita Jintan added encapsulation and ingredient-stabilisation techniques.
By around 2012 Hada Labo’s domestic growth had plateaued, and the old reflex reappeared: a model that spent some 27% of sales on advertising had won the expanding market but became an efficiency drain as it matured — the same structural problem that had surfaced at the 1983 stomach-medicine defeat, returning thirty years on in skincare. Rohto kept widening anyway, in directions no outside-capital-driven firm would easily take. In 2013 it set up a regenerative-medicine unit and moved into cell therapy using allogeneic adipose-derived stem cells; in February 2016 it launched an outside-challenge-work scheme letting employees take side-jobs — rare among listed Japanese firms and, unusually, prompted by staff rather than management.
The reckoning with maturity then sharpened. In 2018 president Toshiaki Yoshino died suddenly of a heart attack at 67, and Kunio Yamada returned as chairman and president before, in June 2019, Masashi Sugimoto — from Takeda — became Rohto’s first president hired from outside the founding family. Ownership stayed with the family; execution was opened to a professional. Through the year to March 2022 Rohto held down promotional spending in Japan and Asia and improved its operating margin for three straight years, retuning the advertising-heavy, growth-first model of the Terurō era toward profitability — while pushing upstream from over-the-counter drugs and cosmetics into prescription and advanced medicine, from regenerative therapies to ophthalmic drugs, under a “Connect for Well-being” healthcare vision that places well-being at the centre of what it sells.
The heart of this decision was that, rather than rescue a bankrupt company whole, Rohto extracted only the intangible asset left inside it: the brand. To take on the rebuilding would have meant carrying about $6.7M (¥2bn) in liabilities and several hundred employees. Rohto shouldered none of that, inheriting only the established brand and its customers and handling production with its own strength in mass-producing a narrow range. Sparing itself the time and expense of building a brand from nothing through advertising while walling off the burdens of the failed firm — it can be read as a design fixed wholly on keeping the entry fee small in the mature market for mass-market drugs.
A borrowed brand, though, is not one’s own. Ōmi Kyōdaisha came back with Mentāmu, so there was no monopoly, and a structure that leaned on a licence kept a weakness that could waver with the terms of the contract. That is precisely why, thirteen years later, Rohto bought the source company itself and raised its right to use into a right to own. Carving out only the brand at the moment of bankruptcy was a deft, light-footed entry and at the same time carried within it the homework of eventually having to own the source. Enter light, decide heavy later — the character of this move as a doorway into diversification shows through it clearly.
The heart of this decision was answering, on the side of ownership, a two-way choice: leave the rights to a brand it had grown in another company’s hands, or own the source outright and take back sovereignty over it. Royalties swelled in proportion to sales, and every renewal reopened the terms; for as long as it was borrowing, the premise of the business always lay in the other party’s grasp. Rohto bought the source company knowing it meant higher costs in the short run, and took manufacturing, sales and the trademark together in one hand. From a right to use to a right to own — the 1975 decision to take only the brand rather than buy the company was here turned over and raised into a decision to acquire the company entire.
Ownership, though, was no cure-all. What was inside the company it had bought fell short of expectations, and the burden of integration — a firm of some five hundred employees now running an overseas business — was far from small. Even so, without this first full-scale overseas acquisition Rohto would have had neither its expansion into China and the rest of Asia under the Mentholatum banner nor the discretion to set prices and products itself. To borrow and defend, or to own and attack — Rohto chose to attack, and in this single episode carved into itself the template for the global expansion and the M&A that would follow.
Turning an unrelated field into an extension of strength
The heart of this decision was that Rohto found its way out of dependence on pharmaceuticals not in a wholly unrelated field but in an extension of its own strength — skin science. Examples of drug makers succeeding in cosmetics were scarce, yet Rohto entered by focusing on how well an ingredient works and offering high function at a low price, which also fit the growing drugstore channel. It recast the knowledge of skin and ingredients accumulated in eye drops and topical medicines directly into the appeal of a cosmetic — more accurately seen as a decision to shift its position sideways than as an adventure.
The Rohto-style model, though — narrow the range, spend heavily on advertising and take the market — is exposed to the pressure of commoditisation once a market matures. Indeed, Hada Labo’s domestic growth eventually ran its course, leaving the task of raising the next lead product. That the shift from pharmaceuticals to cosmetics was a success is beyond doubt; but the cosmetics business too will one day have to give way to the next pillar. Onto which business to project a strength next — this decade-long diversification is a case in which a mature company answered, once and well, in the form of cosmetics, that question it is asked again and again.
The heart of this move can be read as a company that earns its money from eye drops and lotions deliberately spending resources on cell therapy — a field whose time horizon and uncertainty are nothing like those of the products on its shelves. Regenerative medicine demands long years and enormous sums to reach approval, with a high chance of foundering along the way; for anyone sharply answerable for quarterly profit, it was a hard area to choose. There is no denying that it was precisely because the founding family led the management and Rohto could keep its distance from the short-term pressure of outside capital that it could go on staking research resources, in decade-long units, on a field whose payoff it could not read in advance.
If Hada Labo in 2001 was a crossing that widened a pharmaceutical formulation into cosmetics, the 2013 entry into regenerative medicine was a further crossing still — into the realm of cells, outside medicine itself. From eye drops to cosmetics, from cosmetics to food and farming, and on to cells, Rohto has redrawn the outline of its founding trade little by little. That said, the practical use of ADR-001 is still in the middle of clinical work, and whether this long-term investment will bear fruit as a pillar of earnings cannot be foreseen as of this writing. How much fruit the attempt to graft advanced medicine onto a base built with mass-market drugs will return over the next decade remains an open question.
The contrarian HR of a company with no outside capital
The heart of Outside-Challenge Work can be read less in the permitting of side-jobs itself than in taking an idea proposed by employees and moving it straight into a formal scheme, swinging the very corporate philosophy over to the side of challenge. As scale became hard to picture in a mature domestic market, Rohto sought the source of its growth not in plant or acquisitions but in the quality of its people. Opening a circuit to bring experience gained outside the company back into the core work was also a quiet attempt to break down the conventional view of employment that pens talent into a single job. It is discernible that what made this contrarian move possible was an independence that let the founding family keep the initiative even as a listed company, hard to bind to the market’s short-term judgement.
How far the scheme bore fruit in talent and results, though, is still being judged. Two years after it began, in 2018, President Toshiaki Yoshino died suddenly, and Kunio Yamada of the founding family returned as chairman and president, after which the axis of management shifted toward holding down promotional spending and prioritising the profit margin. How an HR scheme raised under the banner of challenge would coexist with a management bent on earnings efficiency in a mature phase was a question left for afterward. How much of the experience employees opened outward through side-jobs comes back into new businesses and culture at the core — that answer, it seems, will be measured as the years of the scheme accumulate.
The heart of this succession can be read less in coping with the accident of a president’s sudden death than in a family firm of a hundred and twenty years opening execution to the outside while keeping its own independence intact. The capital design laid down at the 1949 incorporation, holding outside capital in check, had made possible contrarian diversification — the lifting of the side-job ban, the move into regenerative medicine — without watching for other companies’ reactions. That independence had been guaranteed in large part by the founding family sitting at the top. Toshiaki Yoshino’s sudden death shook that premise and at the same time, it seems, became the occasion to test the next form: entrusting execution alone to a professional without letting go of ownership.
A structure in which Kunio Yamada stayed on as a chairman holding representative authority while Masashi Sugimoto, from Takeda, took charge of operations as president can be called an attempt to bind the family’s centripetal pull and outside discipline into one. The more a company widens the base of its businesses against selection-and-concentration, the more discipline it needs to make each diversified business pay. Whether it can raise every one of the operations it has spread into total healthcare into a profitable form without thinning the spirit of challenge that the founding family’s independence breeds is what will test the ability of the manager brought in from outside. The question of where a family firm acquires the management discipline to match its scale and diversification remains, even after the 2019 succession, an open one.
Each heading links to the full Japanese analysis — background, decision and outcome, with sources.
This is a condensed English edition. The full, source-by-source history — with the detailed narrative, financial tables, shareholders and executives — is maintained in Japanese: 日本語版（詳細）— Rohto Pharmaceutical full history in Japanese →